These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10780728)

  • 1. Effects of hydroxyurea on T cell count changes during primary HIV infection.
    Ravot E; Tambussi G; Jessen H; Tinelli C; Lazzarin A; Lisziewicz J; Lori F
    AIDS; 2000 Mar; 14(5):619-22. PubMed ID: 10780728
    [No Abstract]   [Full Text] [Related]  

  • 2. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amsterdam Duration of Antiretroviral Medication (ADAM) study.
    Torres RA; Bellman PC; Barr M
    Lancet; 1998 Oct; 352(9134):1149. PubMed ID: 9798619
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
    Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
    J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of immune modulation in primary HIV infection.
    Lori F; Lisziewicz J
    J Biol Regul Homeost Agents; 2000; 14(1):45-8. PubMed ID: 10763893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-HIV agents. Long-term use of hydroxyurea.
    TreatmentUpdate; 2000 Sep; 12(6):2-3. PubMed ID: 12132459
    [No Abstract]   [Full Text] [Related]  

  • 8. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
    De Boer RJ; Boucher CA; Perelson AS
    AIDS; 1998 Sep; 12(13):1567-70. PubMed ID: 9764774
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
    López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
    AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of HIV treatment with Hydrea (Hydroxyurea).
    Baker B
    Posit Aware; 1998; 9(5):54. PubMed ID: 11365897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea for HIV?
    Treat Rev; 1998; (No 28):10-2. PubMed ID: 11365419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hydroxyurea and HIV infection].
    Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
    Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
    Lori F; Lisziewicz J
    Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of hydroxyurea in HIV-1 infected patients.
    Frank I
    J Biol Regul Homeost Agents; 1999; 13(3):186-91. PubMed ID: 10560754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.
    Lori F; Foli A; Maserati R; Seminari E; Xu J; Whitman L; Ravot E; Alberici F; Lopalco L; Lisziewicz J
    HIV Clin Trials; 2002; 3(2):115-24. PubMed ID: 11976989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term suppression of HIV-1 by hydroxyurea and didanosine.
    Lori F; Jessen H; Foli A; Lisziewicz J; Matteo PS
    JAMA; 1997 May; 277(18):1437-8. PubMed ID: 9145714
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
    Lori F
    AIDS; 1999 Aug; 13(12):1433-42. PubMed ID: 10465065
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.